Posted by Michael Wonder on 08 Jul 2020
Lynparza approved in the EU for BRCA mutated metastatic pancreatic cancer
8 July 2020 - Only PARP inhibitor approved in this disease.
AstraZeneca and MSD today announced that Lynparza (olaparib) has been approved in the European Union for patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer.
Approximately 5-7% of patients with metastatic pancreatic cancer have a germline BRCA mutation.
